Groove pancreatitis is a focal form of chronic pancreatitis affecting the area of the paraduodenal groove. The aim of this systematic review was to assess the clinical presentation, diagnosis and treatment of patients with groove pancreatitis. Medical literature databases (Embase, Medline via PubMed and Cochrane Central Register of Controlled Trials) were systematically searched for data recorded between 1 January 1990 and 31 August 2022 regarding patient characteristics, diagnosis, surgical treatment and outcomes. The following inclusion criteria were applied: RCTs, observational studies (cohort and case–control studies) and case studies with >3 cases including patients with groove pancreatitis undergoing medical, endoscopic or surgical treatment with available clinical and diagnostic data. Fisher’s exact test for binary data and Mann–Whitney U test or Student t-test for continuous data were adopted for statistical analysis. Of 649 studies, 44 were included, involving reports on 1404 patients with a mean age of 49 years. In 41 of the 44 studies in which patient gender was described, 86 per cent (N = 1023) of patients were male. Information on the risk factors of alcohol and nicotine was available in 37 and 23 studies, respectively. Seventy-nine per cent (N = 886) of patients had a history of excessive alcohol consumption and 83 per cent (N = 595) were smokers. Information on clinical symptoms was available in 37 of the 44 included studies and 78.5 per cent (N = 870) presented with abdominal pain. Some 27 studies comprising 920 groove pancreatitis patients were treatment oriented. Seventy-four per cent (N = 682) of patients were treated conservatively, 26.4 per cent (N = 134) underwent endoscopic treatment and 54.7 per cent (N = 503) required surgery. There was complete relief of symptoms in 35.6 per cent (N = 243) after conservative treatment, 55.2 per cent (N = 74) after endoscopic treatment and 69.6 per cent (N = 350) after surgical treatment. The median follow-up time was 42 months (range, 1–161 months). Groove pancreatitis shows on imaging a typical triad: cystic lesions in the pancreatic duct or duodenal wall, calcifications, and thickenings of the duodenal wall. Surgery appears to be the most effective treatment modality.

Zusammenfassung. Die akute Cholezystitis gehört zu den häufigsten akuten chirurgischen Krankheitsbildern. Charakteristisch für die Cholezystitis sind rechtsseitige Oberbauchschmerzen, Fieber und Leukozytose. Mittels Abdomensonographie kann die Diagnose häufig gestellt werden. Es besteht Konsens darüber, dass die laparoskopische Cholezystektomie die Therapie der Wahl darstellt und innerhalb weniger Tage nach Symptombeginn erfolgen soll. Das Risiko für weitere Komplikationen kann durch die frühe Operation reduziert oder verhindert werden. Auch bei Hochrisikopatienten sollte eine frühe laparoskopische Cholezystektomie erwägt und wenn vertretbar, durchgeführt werden. Die konventionell-laparoskopische Cholezystektomie über 3 – 4 Zugänge gilt weiterhin als chirurgischer Standard. und kann mit einer niedrigen Mortalität und Morbidität durchgeführt werden. Chirurgische Komplikationen sind selten, Gallengangsverletzungen gehören zu den Schwerwiegendsten. Chirurgische Komplikationen sind oft technisch bedingt oder Folge mangelnder Erfahrung. Die Morbidität einer laparoskopischen Cholezystektomie kann durch folgende Massnahmen gesenkt werden: Stellen der richtigen Operationsindikation; Beachten der kritischen Operationsschritte; die Hemschwelle zur Konversion soll tief gehalten werden; Adäquates Training der Chirurgen.

Introduction: Over the past two decades, cytoreductive surgery and HIPEC has improved outcomes for selected patients with peritoneal metastasis from various origins. This is a cross-sectional study with descriptive analyses of HIPEC trials registered on ClinicalTrials.gov. This study aimed to characterize clinical trials on HIPEC registered on ClinicalTrials.gov with the primary objective of identifying a trial focus and to examine whether trial results were published. Methods: The search included trials registered from 1 January 2001 to 14 March 2022. We examined the associations of exposure variables and other trial features with two primary outcomes: therapeutic focus and results reporting. Results: In total, 234 clinical trials were identified; 26 (11%) were already published, and 15 (6%) trials have reported their results but have not been published as full papers. Among ongoing nonpublished trials, 81 (39%) were randomized, 30 (14%) were blinded, n = 39 (20%) were later phase trials (i.e., phases 3 and 4), n = 152 (73%) were from a single institution, and 91 (44%) had parallel groups. Most of the trials were recruiting at the time of this analysis (75, 36%), and 39 (20%) were completed but had yet to publish results. In total, 68% of the trials focused on treatment strategies, and 53% investigated the oncological outcome. The most studied neoplasms for HIPEC trials were peritoneally metastasized colorectal cancer (32%), gastric cancer (29%), and ovarian cancer (26%). Twenty different drugs were analyzed in these clinical trials. Conclusions: Many study results are awaited from ongoing HIPEC trials. Most HIPEC trials focused on gastric, colorectal, or ovarian cancer. Many clinical trials were identified involving multiple entities and chemotherapeutic agents.